News | May 25, 2021
Astrazeneca Pharma India Q4FY21 net profit up at Rs 27.27 Cr
The company has reported total income of Rs.826.40 crores for FY 2020-21
The company has reported total income of Rs.826.40 crores for FY 2020-21
The company plans to enter the EU markets in FY22
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
This marks Glenmark's first synthetic decapeptide injectable approval
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients
It posted net profit of Rs.188.77 crores for the period ended March 31, 2020.
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
Subscribe To Our Newsletter & Stay Updated
